Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer
Status:
Completed
Trial end date:
2010-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study was to determine the effects of the weekly regimen of ixabepilone
dosing compared to the once every 3 week dosing regimen in participants with metastatic
breast cancer.